 | Up a level |
Pabst, Thomas; Vey, Norbert; Adès, Lionel; Bacher, Ulrike; Bargetzi, Mario; Fung, Samson; Gaidano, Gianluca; Gandini, Domenica; Hultberg, Anna; Johnson, Amy; Ma, Xuewen; Müller, Rouven; Nottage, Kerri; Papayannidis, Cristina; Recher, Christian; Riether, Carsten; Shah, Priya; Tryon, Jeffrey; Xiu, Liang and Ochsenbein, Adrian F (2023). Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica - the hematology journal, 108(7), pp. 1793-1802. Ferrata-Storti Foundation 10.3324/haematol.2022.281563
Adès, Lionel; Sanz, Miguel A; Chevret, Sylvie; Montesinos, Pau; Chevallier, Patrice; Raffoux, Emmanuel; Vellenga, Edo; Guerci, Agnès; Pigneux, Arnaud; Huguet, Francoise; Rayon, Consuelo; Stoppa, Anne Marie; de la Serna, Javier; Cahn, Jean-Yves; Meyer-Monard, Sandrine; Pabst, Thomas; Thomas, Xavier; de Botton, Stéphane; Parody, Ricardo; Bergua, Juan; ... (2008). Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 111(3), pp. 1078-84. Washington, D.C.: American Society of Hematology 10.1182/blood-2007-07-099978
